Tag: VistaGen

Vistagen’s late-stage CNS pipeline, led by fasedienol™, shows clinical progress and strategic growth despite liquidity pressures and non-material revenue.

Vistagen Therapeutics is making breakthroughs in CNS treatments with PH94B, PH10, and AV-101, offering new hope for anxiety and depression patients.

Discover how VistaGen's cutting-edge Pherine technology transforms treatment for anxiety, depression, and CNS disorders, promising faster, safer therapies.

Discover how VistaGen is leading mental health innovation with novel treatments for anxiety, depression, and CNS disorders, leveraging cutting-edge Pherine technology.